2024-09-20 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and sells a wide range of healthcare products, including medical devices, pharmaceuticals, and nutritional products.

**Performance Analysis:**

**1. Return & Comparison to S&P 500:**

* ABT's cumulative return is 106.18%.
* The S&P 500 (VOO) has a cumulative return of 128.99%.
* ABT lags behind the S&P 500 by -22.81%.
* The relative divergence of -22.81% indicates that ABT's performance is currently below the S&P 500's performance, but it sits at the 18.31 percentile of its historical performance range compared to the S&P 500. 

**2. Recent Price Movement:**

* Closing price: $114.89
* 5-day moving average: $116.67
* 20-day moving average: $114.52
* 60-day moving average: $108.84

The current price is slightly below the 5-day moving average, suggesting a potential short-term downward trend. However, the price is above the 20-day and 60-day moving averages, indicating a longer-term bullish trend.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 57.8 
* **PPO (Percentage Price Oscillator):** -0.09
* **Delta_Previous_Relative_Divergence:** 5.0 (negative)

The RSI indicates that the stock is in a slightly overbought territory, suggesting that a pullback could be expected. The PPO is negative, signaling a potential bearish sentiment. The negative Delta_Previous_Relative_Divergence suggests a short-term downward trend in the stock's relative strength.

**4. Recent Earnings & Outlook:**

| Date       | EPS      | Revenue     |
|------------|----------|-------------|
| 2024-07-31 | 0.74     | 10.38 B$    |
| 2024-05-02 | 0.7      | 9.96 B$     |
| 2023-11-01 | 0.82     | 10.14 B$    |
| 2023-08-03 | 0.79     | 9.98 B$     |
| 2024-07-31 | 0.79     | 9.98 B$     |

The most recent earnings (2024-07-31) show an EPS of 0.74, surpassing analyst estimates. Revenue also came in above expectations, indicating a positive performance. While the EPS shows a downward trend, overall revenue remains consistent. 

**5. Overall Analysis:**

Abbott Laboratories is currently facing some short-term headwinds, indicated by the recent price movement and technical indicators. However, the company continues to demonstrate a strong performance with consistent revenue and recent earnings beating expectations. The long-term trend appears bullish, supported by the 20-day and 60-day moving averages. 

**6. Investment Recommendation:**

While the stock is currently slightly overbought, ABT's long-term growth potential and consistent performance make it a good investment option for those seeking a diversified healthcare portfolio. The stock's expected return of 67.14% over 5 years suggests potential for significant value appreciation. 

**Disclaimer:** This information is for general knowledge and informational purposes only, and does not constitute financial advice. Investment decisions should be made with the guidance of a qualified financial advisor.